![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 4556w CAMBRIDGE ANTIBODY TECHNOLOGY 25th September 1998 CAMBRIDGE ANTIBODY TECHNOLOGY INITIATES PATENT INFRINGEMENT ACTION AGAINST MORPHOSYS Melbourn, UK. Cambridge Antibody Technology Group plc (CAT) announces that it has commenced a patent infringement action against MorphoSys AG in the District Court in Munich Germany. The proceedings ask the Court to, among other things, order MorphoSys to cease immediately any further infringing activity. CAT is committed to enforcing its patents where necessary. The action seeks to stop MorphoSys infringing CAT's patents and does not in any way impact on CAT's freedom to operate its technology. For Further Information Contact: Cambridge Antibody Technology David Chiswell, Chief Executive Officer Tel: +44 (0) 1763 263233 John Aston, Finance Director City/Financial Enquiries Nicola How, HCC.De Facto Financial Tel: +44 (0) 171 496 3300 Notes CAT's patent portfolio originates from a filing by the MRC in 1989. With subsequent patent filings CAT currently has two main patent families covering antibody libraries and phage display. The proceedings claim that MorphoSys infringes two of CAT's patents which underpin its antibody display technology - Winter et al which covers CAT's antibody gene expression libraries and McCafferty et al which covers CAT's phage display of antibody fragments. CAT's Winter patent and McCafferty patent have both been granted in Europe (9 April 1994 and 13 November 1996 respectively). Both are currently in Opposition proceedings with the European Patent Office. MorphoSys AG has opposed both patents. In the US CAT has filed broadly similar patent applications with the United States Patent Office. The McCafferty patent is under examination. The Winter patent application is the senior applicant in an interference action within the US Patent Office which involves other US applications. MorphoSys is not involved in the US proceedings. END MSCPBUWGBBGRGMC
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions